由于安全性或不耐受性原因,从fingolimod转换为ozanimod
Elisabetta Signoriello1, Giuseppe Romano2, Matteo Foschi3,4
1Multiple Sclerosis Center, Second Division of Neurology, Department of Surgical and Medical Sciences, Neurological, Metabolic and Aging, University of Campania Luigi Vanvitelli, Via Pansini 5, Caserta, Naples 81100, Italy.
Therapeutic advances in neurological disorders
|July 14, 2025
概括
将多发性硬化症 (MS) 患者从fingolimod转换为ozanimod通过减少淋巴缺血和肝脏问题提高了安全性. 奥扎尼莫德还表现出很高的持久性和有效性,在保持没有疾病活性证据的情况下.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥萨尼莫德是一种选择性基-1-酸盐 (S1P) 受体调节剂,用于治疗多发性硬化症 (MS).
- 另一种S1P调节剂Fingolimod可能会引起安全问题,如淋巴缺血和肝酶升高.
- 这项研究调查了由于安全问题而将MS患者从fingolimod转换为ozanimod的情况.
研究的目的:
- 为了比较出于安全原因从fingolimod转换为ozanimod的MS患者的治疗坚持和持续性.
- 为了评估切换对淋巴细胞计数和肝酶的影响.
- 评估患者在ozanimod.com上没有出现任何不良事件 (NADE) 和没有疾病活性证据 (NEDA-3) 的比例.
主要方法:
- 60名复发性复发性多发性硬化症患者的回顾性分析,由于安全原因,他们从fingolimod转换为ozanimod.
- 收集的人口,临床,生物化学和安全数据.
- 评估了淋巴细胞和肝酶动态,治疗持续时间超过6个月,NADE和NEDA-3超过1年.
主要成果:
- 96%的患者继续接受ozanimod治疗,平均时间为1.5年.
- 淋巴细胞数量增加 (p=0.025) 在因淋巴缺血而转换的患者中.
- 过高氨酸血症从fingolimod的21.6%降低到ozanimod的9.3%.
- 93%的人在一年后实现了NADE,88.3%的人在一年后实现了NEDA-3;83.7%的人实现了两者.
结论:
- 从fingolimod转换为ozanimod可以减轻安全问题,如淋巴缺血和超胺血症.
- 奥萨尼莫德在维持疾病控制方面表现出高的治疗持久性和有效性.
- 对于以前用fingolimod治疗过的MS患者来说,ozanimod提供了有利的安全性和有效性概况.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
282
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
282
Allergic Drug Reactions
981
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
981
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
272
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
272
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
204
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
204
Dosage Regimen: Fixed Dose
2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
Inflammatory Bowel Disease IV: Pharmacological Management
198
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
198


